Implementation of patient-reported outcome measures in real-world evidence studies: Analysis of ClinicalTrials.gov records (1999-2021).

Contemp Clin Trials

Centre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK; Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK; National Institute for Health and Care Research (NIHR) Birm

Published: September 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Real-world evidence (RWE) plays an increasingly important role within global regulatory and reimbursement processes. RWE generation can be enhanced by collecting and using patient-reported outcomes (PROs), which can provide valuable information on the effectiveness, safety, and tolerability of health interventions from the patient perspective. This analysis aims to examine and summarise the utilisation of patient-reported outcomes measures (PROMs) in real-world studies.

Methods: Descriptions of phase IV trials were downloaded on July 22, 2021 from the Clinicaltrials.gov database since its inception. An automated algorithm was built to detect trials utilising PROMs and composite measures including patient-reported components. Search terms were developed based on the PROQOLID database.

Results: Of 27,976 phase IV clinical trials posted on Clinicaltrials.gov between 1999 and July 2021, 21% and 4% used PROMs and composite measures, respectively. Recent years demonstrated a steady increase in the utilisation of PROMs in phase IV trials.

Conclusions: The use of PROMs in phase IV trials seems to be lower than its use in earlier phases of clinical research. Increased uptake of PROMs in RWE studies can be facilitated in a number of ways including the development of standards for their collection, analysis and use.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2022.106882DOI Listing

Publication Analysis

Top Keywords

real-world evidence
8
patient-reported outcomes
8
phase trials
8
july 2021
8
proms composite
8
composite measures
8
proms phase
8
proms
6
implementation patient-reported
4
patient-reported outcome
4

Similar Publications

Background/aims: Despite medical advances in recent decades, the mortality rate of advanced liver cirrhosis remains high. Although liver transplantation remains the most effective treatment, candidate selection is limited by donor availability and alcohol abstinence requirements. Bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has shown promise for the treatment of advanced cirrhosis.

View Article and Find Full Text PDF

A Review of the Importance and Relevance of Real-World Data and Real-World Evidence.

Med Sci Monit

August 2025

Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA.

Real-world data are routinely collected data associated with patient health status or delivery of health care from sources including patient registries, electronic health records (EHRs), medical claims data, or digital health technologies. Real-world evidence is generated from specified clinical real-world data and includes evidence of the use, benefits, and risks of a medical product. Analysis of real-world data is the basis of real-world evidence to support the use and potential benefits or risks of a medical product.

View Article and Find Full Text PDF

Diagnostic symptoms, treatment patterns, and healthcare resource utilization in multiple system atrophy in the United States.

Neurodegener Dis Manag

September 2025

RWE Statistics, KMK Consulting, Inc, North Tower, Morristown, NJ, USA.

Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with diverse symptoms that complicate diagnosis. We aimed to characterize MSA-related symptoms, medications, and healthcare resource utilization (HCRU).

Research Design And Methods: This retrospective cohort study used a large US claims database.

View Article and Find Full Text PDF

Large language models (LLMs) represent a transformative advance in artificial intelligence, with growing potential to impact chronic kidney disease (CKD) management. CKD is a complex, highly prevalent condition requiring multifaceted care and substantial patient engagement. Recent developments in LLMs-including conversational AI, multimodal integration, and autonomous agents-offer novel opportunities to enhance patient education, streamline clinical documentation, and support decision-making across nephrology practice.

View Article and Find Full Text PDF

Aims: This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients.

Materials & Methods: A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence.

View Article and Find Full Text PDF